Phase II trial of eribulin for recurrent or metastatic salivary gland cancers.

Eaton, Keith D.; Goulart, Bernardo H. L.; Santana-Dávila, Rafael; Chow, Laura Q.; Wood, Rebecca L.; Rodriguez, Cristina P.; Baik, Christina S.; Martins, Renato

doi:10.1200/jco.2016.34.15_suppl.6095

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regorafenib, a multi-kinase inhibitor of VEGFR, FGFR, and PDGFR, resulted in prolonged stable disease (>6 months) in ACC patients who had documented progression prior to initiation of therapy [40]. Notably, the microtubular inhibitor eribulin showed a 10 % objective partial response rate in a mixed population of salivary patients, but a striking 69 % of patients had some tumor shrinkage on first tumor assessment and the disease control rate was reported at 90 % [41]. Further exploration of the use of eribulin for salivary cancers appears warranted, and the verdict is still out on the role of multi-kinase inhibitors which perhaps may play a role in select clinical situations or in combination with immunotherapy.…”

Section: Biologic Agentsmentioning

confidence: 99%

Systemic therapy for recurrent or metastatic salivary gland malignancies

2016

View full text Add to dashboard Cite

Salivary gland carcinomas are notoriously resistant to therapy and no standard of care exists. Due to the rarity of these malignancies, various histologies, and wide ranging clinical behavior it has been difficult to standardize systemic therapy. We have reviewed clinical prospective studies in the last 15 years with salivary gland malignancies involving cytotoxic chemotherapy and biologic agents including targeted therapies such as anti-HER-2, anti-EGFR therapies, and therapies directed at c-kit. Although the results of most trials are modest at best, there has been an increase in studies for salivary cancer in recent years and there are several promising treatment approaches in evolution. Every effort should be made to treat salivary gland malignancies under a clinical protocol and/or at a large multidisciplinary practice with clinicians experienced in treating these malignancies.

show abstract

Section: Biologic Agentsmentioning

confidence: 99%

Systemic therapy for recurrent or metastatic salivary gland malignancies

2016

View full text Add to dashboard Cite

show abstract

“…Attempts have also been made to use monoclonal antibodies and tyrosine kinase inhibitors such as cetuximab, gefitinib, and lapatinib [46,[60][61][62][64][65][66]. There were no objective therapeutic responses after gefitinib or lapatinib use, but 79% of patients treated with lapatinib had disease stabilization, which in 36% lasted for six months or longer [64].…”

Section: Targeted Therapymentioning

confidence: 99%

“…Particularly promising results were related to treatment with an eribulin inhibitor with an objective partial response rate of 10% [46,65]. It seems that the use of eribulin inhibitors in patients with advanced or metastatic ACC will be a very promising direction for further research.…”

Section: Targeted Therapymentioning

confidence: 99%

“…It seems that the use of eribulin inhibitors in patients with advanced or metastatic ACC will be a very promising direction for further research. Other potential targets of the experiment are fusion transcripts, such as ETV6-NTRK3 [43,46,64,65], which characterise some malignant tumours of the salivary glands and are likely to be further targets for specific inhibitors (NCT02576431).…”

Section: Targeted Therapymentioning

confidence: 99%

See 1 more Smart Citation

Contemporary diagnostic and therapeutic possibilities in patients with adenoid cystic carcinoma of the head and neck

et al. 2020

View full text Add to dashboard Cite

Adenoic cystic carcinoma (SACC, ACC) in the head and neck area, occurring in small and large salivary glands are relatively rare tumors, usually undergoing slow progression. ACC is characterized by a different clinical course compared to other cancers, with a long latency period, a tendency to form late, initially asymptomatic metastases and a small percentage of responses to systemic treatment. This article presents current recommendations for diagnostic procedures and treatment possibilities.

show abstract

First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study

et al. 2019

View full text Add to dashboard Cite

Objectives: There is a lack of effective therapy for recurrent or metastatic salivary gland carcinoma. Androgen deprivation therapy has demonstrated efficacy in cases of salivary duct carcinoma (SDC) and high-grade adenocarcinoma not otherwise specified (NOS) that express androgen receptor. Materials and Methods: We conducted a single institution retrospective cohort study examining patients treated for recurrent/metastatic SDC or high-grade adenocarcinoma NOS of the salivary gland. Survival analyses were performed to assess for efficacy of first-line androgen deprivation therapy (ADT) vs. first-line conventional cytotoxic chemotherapy. Efficacy of salvage ADT was also assessed. Results: Fifty-eight patients were reviewed. Thirty-five patients had recurrent/metastatic disease of which 28 had SDC (80%) and 7 had high-grade adenocarcinoma NOS (20%). Median overall survival for first-line ADT was 25 months compared to 25 months for first-line chemotherapy [RR 0.54 (0.23–1.28, p = 0.16)]. Patients treated with first-line ADT had a response rate of 45% (9/20) and patients treated with first-line chemotherapy had a response rate of 14% (2/14). Six patients received salvage ADT with 1 patient demonstrating complete response and 3 with stable disease as best response (clinical benefit rate 67%). Conclusion: Overall survival for first line ADT and first line cytotoxic chemotherapy was comparable but response rates to first-line ADT were higher than those with first-line chemotherapy. Salvage ADT is active in recurrent/metastatic salivary gland carcinoma.

show abstract

Phase II trial of eribulin for recurrent or metastatic salivary gland cancers.

Cited by 4 publications

References 0 publications

Systemic therapy for recurrent or metastatic salivary gland malignancies

Systemic therapy for recurrent or metastatic salivary gland malignancies

Contemporary diagnostic and therapeutic possibilities in patients with adenoid cystic carcinoma of the head and neck

First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study

Contact Info

Product

Resources

About